4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
("4basebio", the "Company" or the "Group")
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in
CPI's tender process for supplying its
The tender process was focussed on the manufacture of plasmid and synthetic DNA templates, and 4basebio is able to fulfil CPI's DNA requirements for the development and scale-up of novel RNA therapeutics. 4basebio's synthetic opDNA™ templates confer several advantages for the production of mRNA, not limited to superior transcriptional yields and no need for enzymatic linearisation, alongside reduced turnaround time, safety, and cost benefits.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943
Nominated Adviser +44 (0)20 7213 0880
Jo Tuner /
Broker +44 (0)20 7220 0500
Cavendish
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focussed on accelerating the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company' objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.
About CPI
Developing next-generation medicine manufacturing innovations to deliver tomorrow's vaccines and therapeutics. We offer world-leading facilities and expertise in small molecules, biologics, oligonucleotides, and complex medicines to accelerate drug development and scale-up. We host the largest pool of RNA biomanufacturing experts in the
We're creating agile, efficient, and sustainable supply chains by convening actors across the pharma industry ecosystem in a pre-competitive space and boosting the adoption of industry 4.0 advanced processes and digitisation.
We're a pioneering social enterprise that accelerates the development, scale-up and commercialisation of smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.
As a trusted partner of industry, academia, government, entrepreneurs, and the investment community, we connect the dots within the innovation ecosystem to make great ideas and inventions a reality. We believe by working together we can build a better collective future, and as part of the
Creating lasting global impact from the North of
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.